Benitec's Gene Therapy Offers New Hope with Long-Term Data for Rare Muscular Dystrophy

HAYWARD, CA – February 23, 2026 – Benitec Biopharma today announced a significant step forward in the quest for a treatment for Oculopharyngeal Muscular Dystrophy (OPMD), a rare and progressive genetic disorder. The company will present new, long-term clinical data for its gene therapy candidate, BB-301, in a late-breaking presentation at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

The announcement has generated anticipation among researchers and patient communities, as the data will include 24-month follow-up results for the first patient treated in the study, along with 12-month results for a larger group. The acceptance of these findings as a late-breaking abstract underscores their potential importance to a field with no disease-modifying therapies.

“We are pleased to present long-term clinical study results for Patients treated with BB-301 in Cohort 1 and interim clinical study results for the first Patient treated with BB-301 in Cohort 2 at the Muscular Dystrophy Association Clinical & Scientific Conference,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “We are grateful to the OPMD community and investigators, and we look forward to providing updates on the ongoing clinical study and future discussions with the FDA as we work toward confirming the pivotal study path for BB-301.”

A Disease in Need of a Breakthrough

Oculopharyngeal Muscular Dystrophy is a cruel and slowly progressing disease that typically emerges in middle age. Caused by a mutation in the PABPN1 gene, it leads to the progressive weakening of specific muscles. The first signs are often subtle: drooping eyelids (ptosis), which can eventually impair vision, and a gradual weakening of the limbs.

However, the most severe and life-altering symptom is dysphagia, or difficulty swallowing. For the estimated 97% of OPMD patients who experience it, dysphagia transforms the simple act of eating into a daily struggle. It begins with difficulty swallowing dry foods and progresses to liquids and even saliva. This can lead to chronic choking, severe weight loss, malnutrition, and a life-threatening condition called aspiration pneumonia, where food or liquid enters the lungs.

Currently, there is no cure. Patients rely on a regimen of supportive care to manage their symptoms. This can include specialized swallowing therapies, surgical procedures to cut throat muscles (cricopharyngeal myotomy) for temporary relief, or in advanced cases, the placement of a feeding tube directly into the stomach. While these interventions can help, they do not stop the underlying disease progression. The primary unmet need in the OPMD community is a therapy that addresses the root genetic cause.

A Novel 'Silence and Replace' Strategy

Benitec's BB-301 aims to be that therapy. It is built on the company's proprietary DNA-directed RNA interference (ddRNAi) platform, which employs a unique “Silence and Replace” mechanism. This dual-action approach is specifically designed for genetic disorders like OPMD where the mutant protein is not just non-functional but actively toxic to cells.

The therapy is delivered via a single administration using a modified adeno-associated virus (AAV9), a well-studied viral vector chosen for its ability to target muscle cells. Once inside the cells, the BB-301 construct performs two critical jobs simultaneously:

1. Silence: It uses RNA interference (RNAi) to find and degrade the genetic instructions from the faulty, mutated PABPN1 gene. This effectively silences the production of the toxic protein that causes muscle cell damage.
2. Replace: At the same time, the construct delivers a healthy, codon-optimized copy of the PABPN1 gene. This provides the cell with the correct blueprint to produce the functional protein necessary for normal muscle health.

This sophisticated approach is what sets BB-301 apart. Simply adding a correct gene would not be enough to stop the damage caused by the existing toxic protein. By both silencing the bad and replacing it with the good, BB-301 is designed to halt disease progression at its source.

Navigating the Path to Patients

The journey for any new therapy, especially a novel gene therapy for a rare disease, is long and complex. The upcoming presentation at the MDA conference marks a crucial milestone in this journey. The data comes from the ongoing Phase 1b/2a clinical study, which is designed to evaluate the safety, tolerability, and preliminary clinical activity of BB-301 in patients with moderate dysphagia.

Benitec's path has been bolstered by key regulatory designations that recognize the significant unmet need in OPMD. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted BB-301 Orphan Drug Designation. This status provides incentives like market exclusivity and fee waivers to encourage the development of treatments for rare conditions that might otherwise be overlooked.

Furthermore, the FDA has granted BB-301 Fast Track Designation. This is intended to expedite the development and review of drugs for serious conditions that fill an unmet medical need. It allows for more frequent communication with the FDA and enables a “rolling review,” where the company can submit sections of its marketing application as they are completed, potentially shortening the overall approval timeline.

These designations, combined with promising clinical data, are essential as Benitec prepares for discussions with regulators about designing a larger pivotal study—the final stage of clinical testing required before a drug can be considered for market approval.

Long-Term Data Signals Key Milestone

The scientific community and patient advocates will be watching the presentation in Orlando on March 9th with keen interest. The poster, titled “Durable Responses to Low-Dose BB-301 in Oculopharyngeal Muscular Dystrophy at 12- and 24-months and Improved Depth of Response to High-Dose BB-301,” hints at the two most critical factors for a successful gene therapy: durability and dose response.

For a treatment intended to be a single administration, demonstrating a durable effect is paramount. The 12- and 24-month follow-up data will provide the first long-term look at whether the initial benefits observed in patients are sustained over time. Furthermore, the inclusion of initial results from the first patient treated in a higher-dose cohort is a vital piece of the puzzle. This data will help determine the optimal dose to maximize therapeutic benefit while maintaining a strong safety profile, a key question that must be answered before advancing to a pivotal trial.

The presentation of these results at a major scientific conference represents a moment of validation for Benitec's platform and a tangible sign of progress for a patient community that has waited decades for a treatment that targets the cause of their disease, not just the symptoms.